3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
21
Neoplasms
3
Neoplasm Metastasis
3
Prostatic Neoplasms, Castration-Resistant
2
Metastatic Hormone-sensitive Prostate Cancer
2
Metastatic Castration-Resistant Prostate Cancer
2
Small Cell Lung Carcinoma
1
Recurrence
1
Prostate Adenocarcinoma
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma, Follicular
1
Colorectal Neoplasms
1
Castrate Sensitive Prostate Cancer
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Bulbo-Spinal Atrophy, X-Linked
1
Bites and Stings
1
Advanced Prostate Cancer
1
Adenocarcinoma
1
Interventions
Prednisone
4
Docetaxel
4
enzalutamide
2
olaparib
1
niraparib
1
ibrutinib
1
fludrocortisone acetate
1
darolutamide
1
cabazitaxel
1
abiraterone
1
Rosuvastatin Calcium
1
Pluvicto
1
Pioglitazone
1
JNJ-64619178
1
JNJ-64264681
1
Dexamethasone
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Prostatic Neoplasms, Castration-Resistant
×
enzalutamide
×
30 days
×
Clear all
NCT05997615
2026-06-04
AMX-500
Vir Biotechnology, Inc.
Phase 1
Recruiting
437 enrolled
NCT06863272
2026-05-29
IDeate-Prostate02
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
360 enrolled